Compare GSK plc (GSK) vs Simon Property Group Inc (SPG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Simon Property Group Inc — how do they compare? GSK plc trades at $50.33 (market cap $102.60B), while Simon Property Group Inc trades at $219.28 (market cap $71.03B). The key difference: GSK plc is the larger of the two by market cap, and Simon Property Group Inc pays the higher dividend (4.05%). Which is the better fit depends on your goals.
| GSK | SPG | |
|---|---|---|
Market Cap | $102.60B | $71.03B |
Sector | Health | Real Estate |
52-Week High | $61.18 | $236.70 |
52-Week Low | $38.22 | $169.22 |
Enterprise Value | $123.04B | $99.48B |
Dividend Yield | 3.57% | 4.05% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $50.27, down 3.62% today, with a bearish technical signal but strong fundamentals including a P/E of 16.02 and net income margin of 14.52%. Recent quarters show earnings beats, and the company announced a $2.52 billion cost-saving plan to boost its drug pipeline. Cash flow from operations remains robust at $7.74 billion for 2025.
The outlook is mixed: analyst consensus leans hold (55.18%) amid valuation concerns, but revenue growth and pipeline investments support long-term potential. Key risks include competitive pressures and regulatory uncertainty, as highlighted by recent news on vaccine policies. The stock offers a dividend yield with payments scheduled through 2026.
Simon Property Group (SPG) trades at $220.31, down 0.11% on the day, with a bearish technical signal as price tests support near $218. The company reported strong Q2 2026 FFO of $3.29 per share, beating estimates, and raised full-year guidance, driven by robust leasing and retailer sales growth. Financials show high profitability with a net income margin of 66.57% and ROE of 135.7%, though valuation ratios like P/S of 10.29 and P/B of 16.16 appear elevated.
Outlook remains positive with analyst consensus favoring a Buy rating and a $226.58 price target, supported by operational strength and dividend reliability. Key risks include high leverage with $24.21B in long-term debt and sensitivity to interest rates. Earnings growth and strategic acquisitions present upside, but macroeconomic headwinds could pressure retail real estate demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Simon Property Group Inc
Simon Property Group is the second- largest real estate investment trust in the United States. Its portfolio includes an interest in 207 properties: 119 traditional malls, 69 premium outlets, 14 Mills centers (a combination of a traditional mall, outlet center, and big-box retailers), six lifestyle centers, and five other retail properties. Simon's portfolio averaged $693 in sales per square foot over the 12 months prior to the pandemic. The company also owns a 21% interest in Klepierre, a European retail company with investments in shopping centers in 16 countries, and joint venture interests in 33 premium outlets across 11 countries.
Read more on SPG →
